Iambic Therapeutics IPO Gets $60M Anchor Interest from ARK and Duquesne

summarizeSummary

Iambic Therapeutics is moving forward with its IPO, offering 9.375 million shares at $15-$17 each, targeting up to $159.4 million. The new development is that ARK Investment Management and Duquesne Family Office have indicated interest in buying up to $60 million of the offering at the IPO price. That's a meaningful anchor commitment from two well-known investors, signaling demand for the AI-driven drug discovery company. The underwriters also have a 30-day option to purchase up to 1,406,250 additional shares. Listing is expected on Nasdaq under the symbol IAM, contingent on approval.

check_boxKey Events · Financing and Capital Events · IAM

auto_awesomeAnalysis · IAM · Life Sciences